Instrument Inactif

Autres langues Idenix Pharmaceuticals Inc

Actions

US45166R2040

Produits pharmaceutiques

Cours en clôture Nasdaq
- ^USD	-

29/07/14	Idenix Pharmaceuticals : Merck dépasse les attentes malgré la concurrence des génériques	RE
29/07/14	Merck : dépasse les attentes au T2 malgré les génériques	RE

Autres langues

04/02/15	AbbVie : Merck says hepatitis C drugs to lose breakthrough status
10/06/14	Apple : Wall St. edges up, lifted by mergers, acquisitions
10/06/14	Idenix Pharmaceuticals : INVESTOR ALERT: Levi & Korsinsky, LLP Announces Investigation of Idenix Pharmaceuticals, Inc. and Its Board of Directors In Connection With the Sale of the Company to Merck
10/06/14	Idenix Pharmaceuticals : Ryan & Maniskas, LLP : Announces Investigation of Idenix Pharmaceuticals Inc.
10/06/14	Apple : U.S. futures dip, S&P 500 comes off fourth straight record
09/06/14	Bank of America : Dow, S&P 500 extend string of record closes; VIX up
09/06/14	Idenix Pharmaceuticals : INVESTOR ALERT: Levi & Korsinsky, LLP Announces Investigation of Idenix Pharmaceuticals, Inc. and Its Board of Directors In Connection With the Sale of the Company to Merck
23/05/14	Idenix Pharmaceuticals : Clinical Test Results, Improved Medical Care, and Rejection of Buyout Proposal by Medical Companies - Analyst Notes on AstraZeneca, LifePoint, Insmed, Dendreon and Idenix Pharmaceuticals
24/03/14	Idenix Pharmaceuticals Intends to Appeal Norway District Court Decision Regarding Patent Invalidity Case
14/03/14	Idenix Pharmaceuticals Inc : Files Patent Infringement Lawsuits Against Gilead Sciences in Europe
29/01/14	Idenix Pharmaceuticals Announces Decision by the United States Patent and Trademark Office Patent Trial and Appeal Board in the First Patent Interference
28/01/14	Idenix to Raise $106.7 Million Through Registered Direct Offering
20/12/13	Idenix Pharmaceuticals Inc : Price Movements, Leadership Appointments, Patient Enrollments and Supply Agreements - Research Report on Santarus, Hologic, Brookdale, Idenix, and Biodel
09/12/13	Idenix Pharmaceuticals Inc : Idenix Pharmaceuticals Announces Declaration of Senior Party in a Second Patent Interference by the USPTO
25/11/13	Idenix Pharmaceuticals Inc : Idenix Pharmaceuticals to Present at Two Upcoming Healthcare Conferences
30/10/13	Idenix Pharmaceuticals Inc : Idenix Pharmaceuticals Reports Third Quarter and Nine Month 2013 Financial Results and Provides HCV Pipeline Update
28/10/13	Idenix Pharmaceuticals Inc : Idenix to Host Conference Call Discussing Third Quarter and Nine Month 2013 Financial Results and HCV Pipeline Update on Wednesday, October 30, 2013
01/10/13	Idenix Pharmaceuticals Inc : Idenix Pharmaceuticals Announces Nucleotide Prodrug Program Poster Presentation at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting
07/08/13	Idenix Pharmaceuticals Inc : Idenix Pharmaceuticals Reports Second Quarter and Six Month 2013 Financial Results
06/08/13	Idenix Pharmaceuticals Inc : Idenix Pharmaceuticals, Inc. to Hold Second Quarter and Six Month 2013 Financial Results Conference Call on Wednesday, August 7, 2013
20/06/13	Idenix Pharmaceuticals Inc : Idenix Pharmaceuticals Announces Update on Development Program for Its Lead HCV Nucleotide Prodrug Candidate, IDX20963
11/06/13	Idenix Pharmaceuticals Inc : Idenix Pharmaceuticals to Present at the Wells Fargo Securities 2013 Healthcare Conference
10/06/13	Idenix Pharmaceuticals Inc : Idenix Pharmaceuticals Appoints Charles Rowland to Its Board of Directors
30/05/13	Idenix Pharmaceuticals Inc : Idenix Pharmaceuticals Announces Initiation of Phase II All-Oral Combination Study of Samatasvir (IDX719) and Simeprevir (TMC435) for the Treatment of Hepatitis C Virus (HCV) Infection
08/05/13	Idenix Pharmaceuticals Inc : Idenix Pharmaceuticals to Present at Three Upcoming Healthcare Conferences